Angiocrine Bioscience, Inc.

DUBLIN, Jan. 10, 2024 /PRNewswire/ -- The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering. Industry Analysis Unveils Consolidation Dynamics and Regional Market Expansion The global cord blood and tissue banking industry is undergoing a period of significant transformation characterized by robust merger and acquisition activities, technological innovation, and market expansion. A new research publication delves into the intricacies of this dynamic market, offering in-depth insights into current trends, future projections, and strategic developments through 2030. Amidst the spotlight on the healthcare sector for tailored and advanced therapeutic solutions, cord blood and tissue banking has emerged as a pivotal component. Cord blood, known for its potent hematopoietic stem cells, has a track record of over 40,000 transplants worldwide, heralding a new era in treatment options for a myriad of diseases. This comprehensive analysis not only highlights the milestones achieved in cord blood and tissue transplants but also sheds light on the storage capabilities of both public and private banks worldwide. Strategic Developments and Market Segmentation Public and private cord blood banks' cryopreservation units Global utilization of cord blood cells in regenerative medicine Emerging technologies enhancing public banks' financial sustainability Expansion services in the realm of cord blood banking Highlighting the geographical market expanse, the report underscores India's and China's dominant positions, collectively housing over a third of the world's population. Such demographics present vast opportunities for cord blood and tissue banking services. LifeCell International's commanding presence in India, managing over 320,000 stem cell units, exemplifies the regional market's potential. The U.S landscape has not been left behind in the wave of industry consolidation, with major players like CooperSurgical and Cryoholdco cementing their status through strategic acquisitions. With a focus on enhancing comprehensive cord blood banking services, the industry is witnessing expanded offerings that include reproductive services, genetic testing, and cell therapy product development. Furthermore, the report identifies the burgeoning market segments within the cord blood and tissue banking sphere, from storage market revenues and the therapeutic use of cord blood in transplantation medicine to the cutting-edge arena of regenerative medicine applications. Celebrating Scientific Progress and Market Evolution In a market ripe with scientific innovation, such as the groundbreaking FDA approval of Omisirge for recuperating cancer patients' white blood cells, the industry's potential is unmistakable. Moreover, the diverse application in clinical trials, with over 1,200 studies, illustrates the industry's pivotal role in advancing healthcare. The strategic report is an indispensable resource for stakeholders looking to navigate the complexities of the cord blood and tissue banking industry. It stands as a testament to the ongoing metamorphosis of this niche yet essential healthcare service, offering a horizon of opportunities for market participants and recipients alike. Advocating for informed decision-making and strategic positioning within the healthcare sector, this publication is an authoritative guide that equips entities with the knowledge to leverage the unfolding trends and optimize their operational footprint in the cord blood and tissue banking markets. As the industry continues to evolve, the insights from this report pave the way for informed dialogue, strategic planning, and competitive positioning within the global cord blood and tissue banking landscape. The report presents findings on the following topics: Number of cord blood and tissue units cryopreserved in public and private cord blood banks worldwide Number of hematopoietic stem cell transplants (HSCTs) performed globally using cord blood cells Utilization of cord blood cells in regenerative medicine clinical trials The decline of the utilization of cord blood cells in HSCT since 2005 Emerging technologies that will influence the financial sustainability of public cord blood banks The future scope for companion products derived from cord blood The changing landscape of the cord blood and tissue banking market Expansion and extension of services by cord blood banks Types of cord blood banks Economic model of public cord blood banks Cost analysis for public cord blood banks Economic model of private cord blood banks Cost analysis for private cord blood banks Profit margins for private cord blood banks Pricing for processing and storage in private banks Rate per cord blood unit in the U.S. and Europe Indications for the use of cord blood-derived HSCs within transplantation medicine Diseases targeted by cord blood-derived MSCs in regenerative medicine Cord blood processing technologies Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research Number and types of patents for cord blood, cord tissue, and placental products Transplantation data from different cord blood registries Companies Mentioned AllCells AlphaCord Americord Registry, Inc. Angiocrine Bioscience Anja Health Personalized Cord Blood Banking Anthony Nolan Baylx, Inc. Be The Match Biocell Center BioEden BioIntegrate, LLC Bloodworks Northwest California Umbilical Cord Collection Program Carolinas Cord Blood Bank (CCBB) Celaid Therapeutics Celebration Stem Cell Centre (CSCC) Cell Care Cellenkos, Inc. Cells4Life Group LLP CellSave Arabia Celularity, Inc. Center for International Blood and Marrow Transplant Research (CIBMTR) CHOC Blood Bank Cleveland Cord Blood Center ClinImmune Cell and Gene Therapy CooperSurgical Cord Blood Bank of Arkansas (CBBA) Cord Blood Center Group Cord Blood Registry (owned by CooperSurgical) Cord for Life CordLife Group, Ltd. CordVida Crioestaminal Cryo-Cell International, Inc. CryoCyte, LLC Cryoholdco Cryolife Cryopoint Cryoviva Biotech Pvt., Ltd. DentCell DKMS gGMBH Duke University School of Medicine European Society for Blood and Bone Marrow Transplantation (EBMT) Ever Supreme Bio Technology, Co., Ltd. ExCellThera FamiCord Group Fate Therapeutics, Inc. Future Health Gamida Cell GeneCell Global Cord Blood Corporation (GCBC) Glycostem Therapeutics Hawaii Cord Blood Bank HealthBaby HealthBanks Biotech Company Ltd. HealthBanksUSA HEMAFUND Hemogenyx Pharmaceuticals IMMUNIQUE Insception LifeBank JP McCarthy Cord Stem Cell Bank Kangstem Biotech, Co., Ltd. Life Line Stem Cell LifebankUSA LifeCell International Pvt. Ltd. LifeSouth Cord Blood Bank Magenta Therapeutics Maze Cord Blood MD Anderson Cord Blood Bank Medipost, Co., Ltd. Mesoblast, Ltd. MiracleCord, Inc. Mononuclear Therapeutics, Ltd. New England Cord Blood Bank, Inc. New York Blood Center OrganaBio PacifiCord PBKM FamiCord Plasticell Ltd. ReeLabs Pvt. Ltd. Restem, LLC San Diego Cord Blood Bank Saneron CCEL Therapeutics, Inc. Sanpower Group SmartCells SSM Cardinal Glennon Children's Medical Center Stem Cell Cryobank, Inc. Stembanc, Inc. StemCyte, Inc. Throne Biotechnologies, Inc. Transcell Biolife Upstate Cord Blood Bank VCANBIO Cell & Gene Engineering Corporation Versity, Inc. ViaCord Vita 34 AG Vitalant Clinical Services World Marrow Donor Association (WMDA) Worldwide Network for Blood & Marrow Transplantation (WBMT) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Each individual's risk of being diagnosed with primary bone sarcoma and their chances of recovery following diagnosis are influenced by a range of unique factors. In 2023, it is anticipated that 4K individuals of all ages in the United States will be diagnosed with primary bone sarcoma, including 2K males and 1.8K females. In 2020, approximately 400 cases were reported among those aged 15 to 19. LAS VEGAS, Nov. 28, 2023 /PRNewswire/ -- Bone sarcoma is a rare and aggressive form of cancer that originates in the bone tissue. It poses significant challenges during its treatment due to several factors. Firstly, its rarity often leads to delayed diagnosis, as symptoms can mimic other common conditions. Additionally, bone sarcoma typically affects children and young adults, making the emotional toll of the disease particularly challenging. Treatment often involves a combination of surgery, chemotherapy, and radiation therapy, which can be physically demanding and cause severe side effects. Moreover, because bone sarcoma tends to occur in the extremities, treatment may require complex and lengthy surgical procedures, potentially affecting mobility and quality of life. Furthermore, the risk of recurrence remains a constant concern, necessitating long-term monitoring and follow-up care. Despite these challenges, ongoing research and advancements in medical technology offer hope for improved outcomes and a better quality of life for those battling bone sarcoma. DelveInsight has recently released a series of epidemiology-based market reports focusing on benign bone sarcoma including Osteosarcoma Market Report, Ewing Sarcoma Market Report, and Chondrosarcoma Market Report. These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032 segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these bone sarcoma markets individually. Osteosarcoma Market Osteosarcoma is a rare bone tumor affecting having an annual incidence of 3.4 cases per million. It is the most prevalent form of bone cancer, primarily developed in the osteoblast cells of bones, with a predilection for long bones near the knee joint. However, it can also manifest in other locations, including the upper leg, lower leg, upper arm, and virtually any bone in the body, including those in the pelvis, shoulder, and skull. It has the potential to invade adjacent tissues, such as tendons and muscles, and can metastasize to distant organs or other bones via the bloodstream. As per DelveInsight analysts, the total incident population of osteosarcoma in the 7MM was ~2K in 2022. The estimates show the highest incident cases of osteosarcoma in the United States with ~1K cases in 2022, and it is expected to increase by 2032. Osteosarcoma is commonly treated through a combination of chemotherapy, surgery, and radiation therapy. Despite some recent developments, limited progress has been achieved since the late 1980s when chemotherapy was added to surgical treatment, leading to improved survival rates. Radiation therapy impacts both normal and cancerous cells, causing various effects. Chemotherapeutic drugs like cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate with leucovorin calcium rescue (HDMTX) are widely used. Additionally, a few FDA-approved products, such as FUSILEV and KHAPZORY, are available for osteosarcoma treatment. As per DelveInsight analysis, the osteosarcoma market size is expected to increase at a significant CAGR by 2032. This growth would be fuelled by the increase in the patient pool and the expected entry of emerging therapies. Osteosarcoma Pipeline Therapies and Companies Lenvatinib: Eisai Naxitamab: Y-mAbs Therapeutics BAY80-6946: Bayer Vactosertib: MedPacto For a comprehensive view of the osteosarcoma market, check out the Osteosarcoma Market Assessment Ewing Sarcoma Market Ewing Sarcoma, a malignant tumor, typically initiates its growth within the bones, with a higher incidence among children and young adults, often manifesting during adolescence. Although it can originate in any bone, it predominantly affects the long bones, such as the thigh bone, shin bone, and upper arm bone. The pelvis bones are also frequently involved. In some cases, the tumor may originate in muscle and soft tissues. Common symptoms include bone stiffness, pain, swelling, or tenderness, along with tissue surrounding the affected bone. As per the assessment done by DelveInsight, the total incident cases of Ewing sarcoma in the 7MM comprised approximately 1.2K cases in 2022 and are projected to increase during the forecasted period. The management of Ewing sarcoma typically adopts a comprehensive approach, which may encompass surgery, chemotherapy, and radiation therapy. The National Comprehensive Cancer Network (NCCN) offers specific chemotherapy regimens for localized and metastatic Ewing sarcoma. For first-line treatment, NCCN suggests VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) for both initial presentations and as primary therapy for metastatic disease. In the second-line setting, NCCN recommends options like Cyclophosphamide and topotecan, Irinotecan + temozolomide ± Vincristine, Ifosfamide, carboplatin, etoposide, and Lurbinectedin. As per the latest Ewing Sarcoma Market Report, the total Ewing sarcoma market size in the 7MM is approximately USD 26 million in 2022 and is projected to increase during the forecast period (2023–2032). The expected introduction of upcoming therapies and the deepened integration of early patient screening, medication management in secondary care, and diverse clinical setups, ongoing research into optimal implementation approaches, and a surge in public awareness will ultimately pave the way for the advancement of efficient treatment choices. Ewing Sarcoma Pipeline Therapies and Companies SECLIDEMSTAT (SP-2577): Salarius Pharmaceuticals ZEPZELCA (LURBINECTEDIN): Jazz Pharmaceuticals and PharmaMar VERZENIO (ABEMACICLIB): Eli Lilly IBRANCE (PALBOCICLIB): Pfizer MECBOTAMAB VEDOTIN (BA3011): Bioatla IOPOFOSINE I 131 (CLR 131): Cellectar Biosciences TP-1287: Sumitomo Pharma Oncology NBRX-109: Inhibrx Explore in-depth for a comprehensive understanding of the Ewing Sarcoma Clinical Trials Chondrosarcoma Market Chondrosarcoma comprises a group of bone tumors originating from cells that overproduce cartilage. Among these tumors, conventional chondrosarcoma is the most frequent type and is generally associated with slow growth. Conversely, rarer subtypes like dedifferentiated chondrosarcoma, myxoid chondrosarcoma, clear cell chondrosarcoma, and mesenchymal chondrosarcoma tend to exhibit a more aggressive growth pattern and have the potential to spread to distant body parts. DelveInsight estimated that the total incident cases of chondrosarcoma in the 7MM comprised approximately 2K cases in 2022 and are projected to increase during the forecasted period. The management approach for chondrosarcoma is contingent upon factors like tumor type, grade, and location, with the grading system serving as the most reliable indicator of clinical prognosis. It is firmly established that surgical intervention remains the gold standard and sole effective treatment for chondrosarcoma, as alternative modalities such as radiotherapy and chemotherapy exhibit limited responsiveness and resistance. Surgical options encompass curettage, radical resection, and amputation, each necessitating comprehensive clinical judgment and contingent upon variables such as lesion size, location, and malignant characteristics. Anticipated advancements in upcoming therapies and increased integration of early patient screening and medication within secondary care and other clinical settings, along with ongoing research to determine the best implementation methods, are expected to contribute to the development of more effective treatment options. However, chondrosarcoma, being an orphan disease, presents challenges in conducting clinical trials. Limited outcome data for locally advanced or metastatic patients underscore the need for new treatment approaches. Phase I trials, due to their small number of chondrosarcoma patients at varying dose levels, make it difficult to draw definitive conclusions. Nevertheless, some Phase II trials have yielded promising results, warranting further investigation. Encouraging retrospective studies could help augment the currently limited data. Urgent efforts to boost research studies on this orphan disease are imperative. As per DelveInsight analysis, the total market size of chondrosarcoma in the 7MM is approximately USD 9 million in 2022 and is projected to increase at a massive CAGR of 24.8% due to increasing awareness of the disease and the launch of the emerging therapy. Chondrosarcoma Pipeline Therapies and Companies INBRX-109: Inhibrx To access a complete analysis of the chondrosarcoma market, visit Chondrosarcoma Market Assessment Trending Oncology Reports Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including GAbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Oncolytic Virus Cancer Therapies Market Oncolytic Virus Cancer Therapies Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oncolytic virus cancer therapies companies, including Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, among others. Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, among others. Oncology Conference Coverage Services DelveInsight's Oncology Conference Coverage Services deliver a comprehensive examination of conference outcomes from a range of prominent events, such as ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, European CAR T-cell Meeting, and IASLC 2023. This in-depth analysis equips businesses with the insights they need for effective competitive intelligence and forecasting market trends, aiding in the development of future strategies. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

SAN DIEGO, Feb. 13, 2023 /PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that it has been selected by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) for a poster presentation on its Phase 3 registration study AB-205-301 (E- CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 is an intravenous investigational engineered cell therapy product being developed for multiple indications. "Our investigators and Angiocrine are honored to be selected by ASTCT & CIBMTR to present at its annual meeting this February," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Michael Scordo's presentation on the trial design of our AB-205 Phase 3 multi-center study (E-CELERATE)." E-CELERATE has been designed to evaluate the efficacy and safety of AB-205 as a treatment for damaged organ stem cell vascular niches caused by off-target cytotoxicity of HDT and prevent the progression of severe multi-organ complications, which can be life threatening and prolong hospitalization. The US Food and Drug Administration has conferred special regulatory status to AB-205 via the Regenerative Medicine Advanced Therapy and Orphan Drug designations for this indication. Additionally, the California Institute for Regenerative Medicine (CIRM) has approved investing $15M in this Phase 3 registration study. Tandem Meetings Info Poster Session: Acute Regimen-Related Toxicity and Supportive Care Session Date: Thursday, February 16, 2023 Session Time: 5:45 PM - 6:45 PM EST Poster Number: 184 Poster Title: A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus SOC in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E–CELERATE; NCT05181540): Trial in Progress About AB-205 AB-205 is an experimental engineered cell therapy consisting of allogeneic E4ORF1+ human umbilical vein endothelial cells (E-CEL® cells). AB-205 is currently being studied in a single, pivotal Phase 3 registration trial, designed to evaluate the efficacy and safety of AB-205 in the treatment of severe multi-organ complications related to systemic, diffuse injury to the stem cell vascular niches of multiple organs sustained during high-dose chemotherapy. More information about the E-CELERATE trial and participating sites may be found at the National Institute of Health's ClinicalTrials.gov website - NCT05181540. About Severe Toxicities and Complications during High-Dose Chemotherapy (HDT) and Autologous Hematopoietic Cell Transplant (AHCT) HDT followed by AHCT is a curative treatment option for eligible patients with aggressive systemic lymphoma. Although highly effective in eradicating aggressive cancer cells, HDT also causes collateral damage to healthy tissue. The initial damage can quickly progress to serious and expensive complications despite state-of-the-art prophylactic measures. Most frequent complications involve the gastrointestinal and immune systems (low blood counts, infections); vital organ involvement can be life-threatening and prolong hospital stay. About the California Institute for Regenerative Medicine (CIRM) CIRM was created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, CIRM's team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies. With $5.5 billion in funding and more than 150 active stem cell programs in its portfolio, CIRM is one of the world's largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go to . About Angiocrine Bioscience, Inc. Angiocrine Bioscience, Inc. is a clinical-stage biopharmaceutical company developing Advanced Reparative Medicines consisting of engineered human endothelial cells (E-CEL cells). Angiocrine utilizes its proprietary E-CEL Platform to create multiple versions of E-CEL cells to repair damaged tissues and organs and to treat serious medical conditions. For additional information, please contact: Investor Relations (877) 784-8496 IR@angiocrinebio.com